Overview

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

Status:
Terminated
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
Phase:
Phase 2
Details
Lead Sponsor:
PharmaMar
Collaborator:
National Cancer Institute (NCI)
Treatments:
Trabectedin